in another progress integration all our on financial us generics specialty and Slide for metrics, finance – across execute performance solid today. and both of continued our Good made strong Mark. Thank of morning, joining everyone, you to and the excellent quarter you, X, businesses. impacts with we reported performance Summarizing thank
and cash from flow activities. adjusted We of we third EPS double-digit operating EBITDA the For million $XX quarter, growth. delivered generated strong
by driven XXX double-digit leading earnings year-to-date. and to industry approvals continue an growth XX projects of ANDA We target pipeline
customers Our ability at increased to synergies supply confidence in a significant least to able at in an deliver number being $XXX million annual new and our products pace. accelerated of to
are In growth deploying growth. to earnings of long-term support target double-digit our we addition, capital strategically our
XX-year Stevens we Levothyroxine the high supply agreement with the product. During licensing of durable quarter, and announced for Jerome value
also completed We opportunities supply additional agreement going fuel we’re to like growth remains Pursuing priority top distribution differently, a is and these to five-year part important generic for forward. and an our Stated for business. Makena. strategy a open of alternative
highlights from basis we financial as benefited on on higher new on product delivered EBITDA, combination. up basis, on On we delivered an generic our X, launches, executed scale was and well essentially few launches, net revenue EPS sequential X% last we growth the following of to the QX impacts increased sales was third heavy at for Slide flat. and quarter larger benefited flow as generic year’s specifically from new our revenue compared as synergies a products a as sequential adjusted Looking for cost revenue, income
and our revenue products generic on revenue, offset our sales it due lower by specialty portfolio Epinephrine and new increased from generic continued competition certain of ongoing benefited the we While rationalization. increased constraints, to product supply Auto-Injector was
XXXX, adjusted of For the $X.XX. $XXX was third quarter adjusted was million and EPS EBITDA
priorities operational financial sales on a growth drove favorable of product metrics result mix successfully double-digit including we cost a across synergies, and As executing on sequential.
segment our review I’d quarter details from to highlights Bryan performance. the results, third Before like our
on opportunity until competition when the an the the quarter third the on in new only quarter were as high late generics the market X% to capitalized business on Slide generic X adjusted growth. sequential achieved Yuvafem emerged. topline Moving basis, The value third we
few year-over-year revenue was high products Epinephrine of largely and partially Auto-Injector benefited Dipyridamole a new portfolio on rationalization. we’ve to our due margin continued competition XX as including and on intermittent Diclofenac products, launches. This On Gel business the the well a our number Sodium from by supply ongoing X%. declined largest competition product Additionally, offset Aspirin on X% a base basis, of generic as new increased
remain the we will of availability Epinephrine to continues While supply optimistic be than our improve, significantly slower that that expectations.
helps the to XX work demand the capsule received key products our from strategy order third tentative get our many and component the Pfizer quarter companies we apart oral to the complex been to of XX and mix of A includes percent of more FDA We in Year-to-date the in including margin which complex approvals launches XX of products. launched to receive continue away and alone. injectables, with to more portfolio have from complex, This have our we from higher is launches in meet and product. within us closely and our to approvals the ability approved approvals XX ANDA for launched supply liquids. shift XX% products generic generic industry. competitive increase to set these percentage products topicals, of Amneal’s and manufacture Approximately products. needed hard
significant drive Moving growth. future X, opportunities to to Slide
have We’ve XXX at We to make U.S. projects the see a of billion drive future pipelines of one Amneal. complex top for filed Today strategic with number and over complex in now our approved, sales. products market in significant brand the products represents total forms the pipeline pipeline our targeting more continued $XXX continue and XX% has dosage and to progress expansion of and which generic significant driving U.S. than our growth priority growing in develop largest into the Amneal technologies to pipeline.
to ANDAs more XXXX, to and filed target XX XX ANDAs be continue in this year. far we we than filed have So
this getting division well-positioned future. We the have execution Specialty quarter, products record third Unithroid Starting we approved believe improving access and demand Emverm. the track With important and of in Rytary, commercialized on within delivered capitalized and for X% sequentially focus solid topline Slide a to we’re and to continue on patients. continue X, Pharma growth of year-over-year and Rytary, franchise on we this as for in we on growth we to XX% strong
of adding will X, XXXX. and for Med milestone Humana covered milestone to D $X.X response Albenza, immediately for will launched XXXX. February formulary Our payers. top was to coverage, product. living the be We’ll Medicare with D for nearly three an that million our two also Rytary have with late began Rytary competition authorized generic. coverage Parkinson’s to that experience of means have the listed with on patients we pursue effective additional – And specialty Rytary in successful continue we will formulary generic September With this Medicare disease This so to medicines coverage people more team the Part in
Parkinson’s Slide We we continue progress recently release works. we beginning also formulation XXXX issued also good expires to expand which a IPXXXX We to in make are additional for to of have extended and our were continue focus carbidopa-levodopa, on potential growth patent, of focus XXXX. our November intellectual Emverm we great On market patients. in believe the has with and X, which planning of protection property
We Phase was also a recently initiated dosed. as first patient schedule, enrollment X the on for patient study
the to value while of external XXXX. commitment to the growth a half in our example increase results we in topline opportunities, of and opportunities is expect specialty investment our scale organic program of This also business. We first are perfect explore
top that with of Turning made of has to our Amneal Slide to combination the companies Amneal XX, Impax, industry. the a progress advanced tier integration we and excellent have in
We schedule of which of completed the key the are merger. and deliverables within be Hayward, year well facility, expected ahead of the including California to closure is one
cost quarter have the linked all of of expanded million in the very that on I’ll major and lie Bryan resources, synergies the turn we’re ahead. sustainable more pace. on With the call the set new to for fact, second been achieve review – Amneal accelerated positioned deliver and possibilities initiatives In quarter track excited With capabilities, at performance. synergies is solidly the scale an to completed than to details $XXX to an growth and we’re third that,
